FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 09/01/2016 |
3. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 3,658(1) | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy)(1) | 03/10/2017 | 03/10/2021 | Common Stock | 29,010 | $2.47 | D | |
Restricted Stock Units(1) | 03/10/2017 | 03/10/2021 | Common Stock | 14,506 | (2) | D | |
Stock Option (right to buy)(1) | (3) | 03/09/2022 | Common Stock | 38,908 | $2.55 | D | |
Restricted Stock Units(1) | (4) | 03/09/2022 | Common Stock | 19,455 | (2) | D | |
Stock Option (right to buy)(1) | (5) | 02/28/2026 | Common Stock | 54,721 | $2.97 | D | |
Restricted Stock Units(1) | (6) | 02/28/2026 | Common Stock | 27,418 | (2) | D | |
Restricted Stock Units | 08/01/2017 | 08/03/2026 | Common Stock | 38,093 | (2) | D | |
Restricted Stock Units | (7) | 02/10/2018 | Common Stock | 36,271 | (2) | D |
Explanation of Responses: |
1. Each security was originally issued by Emergent BioSolutions, Inc. and, as a result of the spin-off of the Issuer from Emergent BioSolutions, Inc. effective on August 1, 2016, was adjusted and assumed by the Issuer. |
2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
3. The stock options were granted on March 10, 2015 and vest in two equal installments on March 9, 2017 and March 9, 2018. |
4. The restricted stock units were granted on March 10, 2015 and vest as follows: 9,727 on March 9, 2017 and 9,728 on March 9, 2018. |
5. The stock options were granted on March 1, 2016 and vest as follows: 18,241 on March 1, 2017, 18,241 on March 1, 2018 and 18,239 on March 1, 2019. |
6. The restricted stock units were granted on March 1, 2016 and vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019. |
7. The restricted stock units were granted on August 3, 2016 and vest as follows: 18,135 on February 3, 2017, and 18,136 on February 3, 2018. |
Remarks: |
Title - SVP, Research and Non-Clinical Development. Exhibit List: Exhibit 24 - Power of Attorney. |
/s/ Benjamin J. Stein, attorney-in-fact | 09/12/2016 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |